China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a partnership with compatriot firm Asclepius Technology Company Group. The agreement, with financial details undisclosed, will see Porton provide development, production, and application services in China for Asclepius’s NK cell project, which has applications in cancer prevention, anti-aging, and medical aesthetics.
Complementary Expertise in Gene and Cell Therapy
Established in 2018, Porton offers an end-to-end CDMO service platform for gene and cell therapy, encompassing plasmids, cell therapy, gene therapy, oncolytic viruses, nucleic acid therapy, and live bacterial therapy. Asclepius, on the other hand, is engaged in the research, development, and manufacturing of immune cell therapy products, with a focus on NK/CAR-NK cell therapies. The company prides itself on its universal CAR-NK, allogeneic NK/CAR-NK, and mRNA-LNP technology platforms.- Flcube.com
